Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications

M Galli, F Franchi, F Rollini, L Ortega-Paz… - Expert review of …, 2023 - Taylor & Francis
Introduction The persistence of elevated rates of ischemic recurrences despite the use of
antiplatelet therapy among patients with atherosclerotic disease together with the …
被引用次数：8 相关文章
[PDF] researchgate.net

[PDF][PDF] Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications

M Galli, F Franchi, F Rollini, L Ortega-Paz, D D'Amario… - 2022 - researchgate.net
Introduction: The persistence of elevated rates of ischemic recurrences despite the use of
antiplatelet therapy among patients with atherosclerotic disease together with the …

Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications

M Galli, F Franchi, F Rollini… - Expert review of …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction The persistence of elevated rates of ischemic recurrences despite the use of
antiplatelet therapy among patients with atherosclerotic disease together with the …

Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications.

M Galli, F Franchi, F Rollini, L Ortega-Paz… - Expert Review of …, 2022 - europepmc.org
The persistence of elevated rates of ischemic recurrences despite the use of antiplatelet
therapy among patients with atherosclerotic disease together with the understanding of the …